Compare Payoneer Global Inc (PAYO) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Payoneer Global Inc vs GeneDx Holdings Corp — how do they compare? Payoneer Global Inc trades at $7.14 (market cap $2.43B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Payoneer Global Inc is the larger of the two by market cap, and Payoneer Global Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Payoneer Global Inc for 61 Days and GeneDx Holdings Corp for 19 Days on average.
| PAYO | WGS | |
|---|---|---|
Market Cap | $2.43B | $2.02B |
Volume | 1,342,701 | 734,640 |
Sector | Technology | Health |
52-Week High | $7.18 | $167.51 |
52-Week Low | $4.27 | $34.51 |
Typical Hold Time | 61 Days | 19 Days |
Enterprise Value | $2.17B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Payoneer Global (PAYO) trades at $7.16 with a bullish technical signal supported by moving averages, though oscillators show neutral momentum. The company reported Q2 2026 earnings of $0.02 per share, missing estimates, but revenue grew 10% excluding interest. Recent news highlights the renewal of Payoneer's partnership with Etsy through 2029 and an agreement to be acquired by Nuvei, announced on June 15, 2026.
The outlook is mixed: analyst consensus is 60% buy with no sell ratings, but earnings misses and a high P/E of 51.18 pose valuation concerns. Key risks include integration challenges from the Nuvei acquisition and competitive pressures in fintech. Upside potential hinges on execution of B2B growth and expansion in India.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
